A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

NCT03115099 · Completed

Last updated 2026-05-28

This study tests the safety of the experimental drug LY3325656 in both healthy volunteers and people with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 80 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2017-05 · est. completion 2018-04

Where 2 sites · Singapore

What this study is testing ClinicalTrials.gov NCT03115099 ↗

Description as written by the study sponsor.

The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes. Information about any side effects that may occur will be collected. It will also investigate how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it. The study consists of two parts. Part A will study healthy participants over approximately 12 weeks and Part B will study participants with type 2 diabetes over approximately 5 weeks, excluding screening. Screening is required within 28 days of the start of the study.

Treatments tested

LY3325656 Drug

Administered orally
Placebo Drug

Administered orally
Liraglutide Drug

Administered subcutaneously
Sitagliptin Drug

Administered orally

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03115099 ↗